+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying patients with type 2 diabetes to identify the risk of developing non-alcoholic fatty liver disease NAFLD during regular clinical care. The study also aims to evaluate how useful a combination therapy of Dapagliflozin and Pioglitazone is in managing these patients. This observational study is sponsored by Boryung Pharmaceutical Co., Ltd and focuses on real-world treatment effects. Participants are patients with type 2 diabetes who are beginning treatment with a fixed-dose combination of Dapagliflozin and Pioglitazone at the start of the study. The study monitors these patients over time without assigning different interventions or placebo groups, observing the natural course and treatment outcomes. Participants will be assessed for NAFLD risk using a simple scoring system at the start of the study. The main measurement is the percentage of patients who have a high risk score for NAFLD. Researchers will collect clinical data and follow patients health during their routine care to understand the relationship between type 2 diabetes, treatment, and liver health. The total duration and specific visit schedules are not detailed.

Age: 19Years +All Genders
2 locations
E

Actively Recruiting

Researchers are evaluating the effects of aspirin and high-intensity statin therapy in people with severe coronary calcification, defined as a coronary calcium score of 300 or higher. The trial aims to understand how these treatments may help prevent atherosclerotic cardiovascular disease ASCVD events in this population. This phase 4, randomized, open-label trial uses a factorial design to assess both aspirin use and statin intensity. Participants are assigned to one of four groups aspirin 100 mgday with high-intensity statin therapy no aspirin with high-intensity statin therapy no aspirin with guideline-directed statin therapy or aspirin 100 mgday with guideline-directed statin therapy. Statin intensity follows the 2026 ACCAHA Guideline on the Management of Dyslipidemia. The study treatment lasts for 3 years, during which participants take the assigned medications. Throughout the trial, participants will be monitored for cardiovascular events and safety outcomes over 3 years. The main outcome is the rate of a composite of ASCVD events. Secondary outcomes include rates of individual cardiovascular events, death from any cause, hospitalization for heart failure, major bleeding, and safety endpoints. Participants will provide informed consent and follow the study protocol with scheduled clinical follow-ups to assess these outcomes.

Age: 40Years - 75YearsAll GendersPhase 4
32 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of clopidogrel for preventing major cardiovascular and cerebrovascular events in patients who have subclinical coronary atherosclerosis detected by imaging but do not need revascularization therapy. This study focuses on primary prevention in these patients, who are at increased risk of heart attacks or cardiac death compared to those without coronary atherosclerosis. The study is a phase 4 interventional trial sponsored by Seoul National University Hospital. Participants will be randomly assigned to one of two groups. One group will take clopidogrel 75mg once daily for at least five years. The other group will not receive any antiplatelet or anticoagulant therapy for at least five years, unless medically needed during follow-up, in which case medication may be prescribed with reporting to the research board. This long-term treatment period aims to assess the prevention of major adverse cardiovascular and cerebrovascular events. During the study, participants will be monitored for major cardiovascular and cerebrovascular events, including heart attacks, strokes, and deaths, at two and five years after the last participant enrolls. Researchers will also track bleeding events and other clinical outcomes. Participants will provide informed consent and undergo assessments related to their cardiovascular health over the course of the study, which continues until the end date in 2031.

Age: 40Years +All GendersPhase 4
61 locations
C

Actively Recruiting

Researchers are assessing the safety and effectiveness of a new drug called tegoprazan a Potassium-Competitive Acid Blocker, P-CAB compared to a standard proton pump inhibitor PPI, rabeprazole, in protecting the stomach and upper digestive tract from bleeding and ulcers. This study involves patients who have heart and vascular diseases and use blood-thinning medications that increase the risk of gastrointestinal GI bleeding. The goal is to determine if tegoprazan is at least as good as rabeprazole over a 12-month period. The study has two main parts. First, a safety surveillance phase enrolls about 300 patients taking tegoprazan daily for six months to monitor for liver issues, increased stomach acid hormone levels, or infections. Then, the main randomized phase will include over 3,300 patients assigned to either tegoprazan 50 mg once daily with placebo rabeprazole or rabeprazole 20 mg once daily with placebo tegoprazan. Both groups will be followed for 12 months while taking their assigned medications. Participants will be regularly checked for GI events like bleeding, ulcers, and stomach pain, as well as cardiovascular events such as heart attack or stroke. The study measures when these events first occur and tracks side effects. Safety is closely monitored through lab tests, symptoms, and medical imaging when needed. The entire trial spans several years, with participants involved for at least 12 months during treatment and follow-up.

Age: 19Years +All GendersPhase 4
45 locations